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Abstract
Background: Recent epidemiological evidence shows that colorectal cancer (CRC) continues to occur in carriers of
pathogenic mismatch repair (path_MMR) variants despite frequent colonoscopy surveillance in expert centres. This
observation conflicts with the paradigm that removal of all visible polyps should prevent the vast majority of CRC in
path_MMR carriers, provided the screening interval is sufficiently short and colonoscopic practice is optimal.
Methods: To inform the debate, we examined, in the Prospective Lynch Syndrome Database (PLSD), whether the time
since last colonoscopy was associated with the pathological stage at which CRC was diagnosed during prospective
surveillance. Path_MMR carriers were recruited for prospective surveillance by colonoscopy. Only variants scored by the
InSiGHT Variant Interpretation Committee as class 4 and 5 (clinically actionable) were included. CRCs detected at the
first planned colonoscopy, or within one year of this, were excluded as prevalent cancers.
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Results: Stage at diagnosis and interval between last prospective surveillance colonoscopy and diagnosis were
available for 209 patients with 218 CRCs, including 162 path_MLH1, 45 path_MSH2, 10 path_MSH6 and 1
path_PMS2 carriers. The numbers of cancers detected within < 1.5, 1.5–2.5, 2.5–3.5 and at > 3.5 years since last
colonoscopy were 36, 93, 56 and 33, respectively. Among these, 16.7, 19.4, 9.9 and 15.1% were stage III–IV,
respectively (p = 0.34). The cancers detected more than 2.5 years after the last colonoscopy were not more
advanced than those diagnosed earlier (p = 0.14).
Conclusions: The CRC stage and interval since last colonoscopy were not correlated, which is in conflict with
the accelerated adenoma-carcinoma paradigm. We have previously reported that more frequent colonoscopy
is not associated with lower incidence of CRC in path_MMR carriers as was expected. In contrast, point
estimates showed a higher incidence with shorter intervals between examinations, a situation that may
parallel to over-diagnosis in breast cancer screening. Our findings raise the possibility that some CRCs in
path_MMR carriers may spontaneously disappear: the host immune response may not only remove CRC
precursor lesions in path_MMR carriers, but may remove infiltrating cancers as well. If confirmed, our
suggested interpretation will have a bearing on surveillance policy for path_MMR carriers.
Keywords: Mismatch repair, Microsatellite instability, Lynch syndrome, Hereditary cancer, Colorectal cancer,
Hereditary nonpolyposis colorectal cancer, Colonoscopy, Endoscopy, Surveillance, Screening, Over-diagnosis
Background
It is commonly agreed that adenomas in the colon may
develop to infiltrating cancers, but the probability for
one single adenoma to do so within a few years is low
[1]. Most hereditary colorectal cancers (CRCs) are not
associated large numbers of adenomas in the intestine,
and to indicate that this is different from the situation
in familial adenomatous polyposis, the term “heredi-
tary non-polyposis colorectal cancer” (HNPCC) was
agreed [2]. HNPCC patients often had a few adenomas
in the large bowel at the time of CRC diagnosis, and
Jass and Stewart proposed that “adenomas do not
occur in large numbers in HNPCC, but develop at a
young age, attain a larger size, often show a villous
configuration, and are more prone to malignant con-
version than sporadic adenomas”. This was referred to
as the “accelerated adenoma-carcinoma sequence” and
became accepted as the cause of CRC in HNPCC [3].
Consequently, it was assumed that colonoscopy with
removal of macroscopically visible adenomas would
prevent CRC in individuals at risk for HNPCC. It was
soon documented that colonoscopy with a three-year
interval reduced both CRC incidence and mortality in
HNPCC kindreds [4, 5]. Compared with non-HNPCC
moderate-risk familial CRC, even single colonoscopy at
middle-age substantially reduced risk for subsequent CRC
[6, 7] and there was no benefit from 3-yearly colonos-
copies over 6-yearly colonoscopies [8].
However, CRC continued to occur despite intensive sur-
veillance [9]. In an attempt to reduce incident CRCs,
Vasen and others proposed shortening the interval be-
tween colonoscopies from 2 to 3 years to 1–2 years [10],
now adopted as an international clinical guideline [11]. It
was also agreed that extended surgery could be considered
in individuals with HNPCC and CRC, recognizing that
secondary prevention of CRC by colonoscopy surveillance
was not always reliable [11].
The mismatch repair (MMR) mechanism is ubiquitous
in nature as a means of repairing DNA damage [12, 13],
and pathogenic variants in four genes: MLH1, MSH2,
MSH6 and PMS2 were identified in HNPCC [14–17].
When cells with inherited pathogenic variants acquire a
second somatic mutation that inactivates the wild-type
allele, the consequence may be an MMR protein defi-
cient tumor with microsatellite instability (MSI). In view
of the wide extracolonic cancer phenotype, HNPCC was
re-named Lynch syndrome (LS) and restricted to inher-
ited cancer caused by a path_MMR gene variant [18].
It has long been suspected that some cancers do
not develop through adenomas in LS, but rather
through a pathway without a visible precursor polyp.
The paradigm that all CRC in LS could be prevented
by removal of macroscopically visible precursor lesions
was not confirmed, even with more frequent surveillance
colonoscopy [9, 10]. The Prospective Lynch Syndrome
Database (PLSD) was established to prospectively fol-
low path_MMR carriers. A key question was to valid-
ate the paradigm that removal of macroscopically visible
adenomas during repetitive colonoscopies would prevent
CRC. We have previously reported that the observed life-
time cumulative incidence of CRC in path_MLH1 and
path_MSH2 carriers was 43–45% despite follow-up ac-
cording to national and international guidelines [19–22].
To further inform the epidemiology of CRC in path_MMR
carriers subjected to repeated colonoscopies, we ex-
amined the association between the time since last
colonoscopy and pathological stage of prospectively
detected CRC.
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Material and methods
The PLSD database design and its inclusion criteria
have been described in detail previously [19, 21]. PLSD
is an international, multicentre database recording pro-
spective observational data on path_MMR carriers under
surveillance by colonoscopy. All path_MMR carriers in
each participating centre were included in the study. The
demonstrated genetic variants were assumed inherited
and were found by genetic testing either prior to, at, or
after inclusion for follow-up. Only variants scored by the
InSiGHT Governance Committee as class 4 and 5 (clinic-
ally actionable) were included. All cancers detected prior
to, at or within one year after the age at the first planned
and performed colonoscopy, were scored as prior or
prevalent cancers and excluded from the analysis when
scoring prospectively observed cancers. The surveillance
strategies recommended by each participating centre are
presented in Table 1.
The following information was used in the statis-
tical analyses: sex, path_MMR variant, age at inclu-
sion, age at last update, age at CRC, type of cancer as
indicated by the first three positions in the Inter-
national Classification of Diseases version 9 (ICD-9)
diagnostic system, the American Joint Committee on
Cancer (AJCC) stage of CRC (I–IV) and the time
since the last colonoscopy preceding the diagnosis of
CRC. All cancers, including cancers prior to or at in-
clusion, were recorded for each carrier. Inclusion was
from the first prospectively planned and completed col-
onoscopy, and all recruits had subsequent follow-up of
one year or more.
Patients with a CRC detected during prospective fol-
low-up were studied in detail. The time since the col-
onoscopy before the one in which the cancer diagnosis
was established, was recorded in months and catego-
rized as < 1.5, 1.5 to 2.5, 2.5 to 3.5 or > 3.5 years since
last colonoscopy. We considered stage III-IV as ad-
vanced. We compared stage in the different time inter-
vals since last colonoscopy, corresponding with the
different clinical guidelines advocating 1, 2 or 3 year in-
tervals between colonoscopies, as slightly longer inter-
vals may occur for several reasons in a clinical setting.
We also compared stage in dichotomized time inter-
vals, more and less than 2.5 years, to compare the most
common current recommendation of 2 years to longer
intervals. We performed a sensitivity analysis excluding
Finland since patients there were recommended 2–
3-yearly colonoscopies rather than 1–2-yearly as in the
other countries and because one out of two variants in
the Finnish series was not shared by others. Statistical
testing was performed by SPSS version 23 (IBM,
Armonk, NY, US). Chi-square test was used to test the
statistical significance at the level of α = 0.05 between
the different colonoscopy intervals.
All collaborating centres undertook genetic testing ac-
cording to national policies. No individually identifiable
data was exported to the PLSD.
Results
In the most recently updated series of the PLSD, 6350
pathogenic variant carriers of mismatch repair genes
(path_MMR) were prospectively observed for 51,646
follow-up years. A total of 707 CRCs were detected, and
stage and interval between last prospective surveillance
colonoscopy and diagnosis were available for 209 patients
with 218 (30.8%) CRCs (9 patients had a metachronous
cancer during follow-up). There were 162 path_MLH1, 45
MSH2, 10 path_MSH6 and 1 path_PMS2 carriers.
The numbers of cancers detected within < 1.5, 1.5 to
2.5, 2.5 to 3.5 and > 3.5 years since last colonoscopy were
36, 93, 56 and 33. Of these CRCs, 16.7, 19.4, 9.9 and
15.1% were advanced stage (III–IV), respectively (p = 0.40;
Fig. 1a). The distribution of cancer stage were similar in
the different colonoscopy intervals, p = 0.34 (Table 2). The
cancers detected more than 2.5 years after the last colon-
oscopy were not more advanced than those diagnosed
earlier than 2.5 years (p = 0.14; Fig. 1b).
When excluding patients from Finland, we found a
similar pattern as when analyzing the whole cohort. A
total of 105 patients were included and 110 cancers were
detected at follow-up. The numbers of cancers detected
within < 1.5, 1.5 to 2.5, 2.5 to 3.5 and ≥ 3.5 years since
last colonoscopy were 22 (20%), 53 (48.2%), 15 (13.6%)
and 20 (18.2%). Of these CRCs, 18.2, 26.4, 6.7 and 15.0%
were advanced stage (III–IV), respectively (p = 0.34).
Mean age at cancer diagnosis was 55 years. There was
no difference between the colonoscopy interval distribu-
tion of those under (n = 110) and those over (n = 108)
55 years (p = 0.138). Stage III cancers were slightly more
frequent among those under 55 years than those over 55
years (22 versus 8, respectively; p = 0.045).
Discussion
We found that CRC stage distribution was not dependent
on time since last colonoscopy. Stage distribution was
similar irrespective of time since the previous colonos-
copy, indicating that additional carcinogenetic mecha-
nisms besides the accelerated adenoma-carcinoma
pathway may have been instrumental in the develop-
ment of some CRCs. Our findings are supported by
another prospective study based on 16,327 colonos-
copies in 2747 patients with path_MMR carriers [23],
which found no correlation between advanced stage
CRC and time since last colonoscopy.
There is convincing evidence that regular colonoscopy
surveillance reduces CRC incidence and mortality in
path_MMR carriers compared to no surveillance [4, 5],
although the surveillance does not prevent the cancers
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as much as might had been expected [19–22]. The add-
itional benefit of surveillance strategies with shorter
interval remains less clear, since the study by Engel et al.
showed no difference of CRC incidence between 1-, 2-
or 3-yearly strategies [23]. We have previously shown
that the recommended interval of 3 years lead to lower
point estimate of cumulative incidence of CRC com-
pared to recommended 1–2 year intervals [22], which
was in conflict with the expected outcome of shorter
than 3 years interval [10]. The purpose of the current
analysis was to study if shorter time between colonos-
copies would result in less advanced cancer stage when
CRC was diagnosed. Although this was not a direct com-
parison of different surveillance strategies, reduced stage
was not found to be the additional benefit of more fre-
quent colonoscopies compared to less frequent. In sum,
our prospective observational data confirm neither lower
incidence nor lower stage of CRCs at diagnosis when
shorter intervals between colonoscopies are recommended.
It has been argued that the effectiveness of a 3-yearly
interval in Finland is influenced by a less severe pheno-
type associated with the founder path_MLH1 variant.
We analyzed the non-Finnish data separately and found
a similar lack of association, indicating that our findings
were not explained by the Finnish series having different
pathogenic variants to the others. We acknowledge that
the aim of the present study was not to study the effects
of different classes of path_MMR variants which would
need different methods and which we aim to do later.
We have chosen to use a statistically simple method
comparing the different intervals between colonoscopies
applied in different centres, as well as longer intervals.
This way of categorizing data and results is of interest
when calculating cost-efficiency of the different strat-
egies for healthcare.
We lack the stage and/or interval information on
about 70% of the total patients registered in the PLSD at
the moment. However, we do have complete information
from the centres contributing to this study (Table 1). All
centres having contributed to the previous PLSD reports
were offered the possibility to contribute.
We do not have detailed information on caecal intub-
ation rate, success of bowel preparation or previous aden-
oma detection rate that are acknowledged key performance
indicators associated with colonoscopy quality in sporadic
CRC prevention [24]. Although there is limited evidence
that they may be associated with the risk of CRC in LS
[25], we have no reason to assume that our observation that
stage distribution is similar across the different surveillance
intervals, is biased by the lack of these data.
The results herein support the hypothesis that in
LS, more frequent colonoscopies detect cancers that
might not have progressed to clinical recognition and
clinical significance. Over-diagnosis is well-recognized
Table 2 Stage distribution by the time since last colonoscopy
before cancer diagnosis
Less than 1.5
years (%)
1.5 to 2.5
years (%)
2.5 to 3.5
years (%)
Over 3.5
years (%)
Stage I 22 (61.1) 46 (49.5) 30 (53.6) 12 (36.4)
Stage II 8 (22.2) 29 (31.2) 21 (37.5) 16 (48.5)
Stage III 5 (13.9) 17 (18.3) 4 (7.1) 4 (12.1)
Stage IV 1 (2.8) 1 (1.1) 1 (1.8) 1 (1.8)
All stages 36 (100) 93 (100) 56 (100) 33 (100)
Fig. 1 Number of CRC in different AJCC stages diagnosed in the
time interval since the last surveillance colonoscopy. a time since
last colonoscopy in intervals of < 1.5, 1.5 to 2.5, 2.5 to 3.5 and > 3.5
years. b Time intervals of less and more than 2.5 years
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in screening science especially in relation to prostate and
breast cancers [26–29]. Whether these over-diagnosed
cancers would have been controlled or even destroyed,
through immune and/or other mechanisms or dwell indo-
lently without causing significant morbidity or mortality,
has nor been fully clarified.
The relatively good prognosis of CRCs noted in our
previous reports from PLSD may reflect that the most
but not all cancers produced by the adenoma-carcinoma
mechanism are prevented, and the majority of the incident
CRCs that we see have a better prognosis because they
arise through different carcinogenetic mechanisms. If so,
colonoscopy to prevent CRC may have had the expected
effect, while (some of) the CRCs that are detected repre-
sent different biological tumor phenotypes.
In parallel with the epidemiological studies mentioned
above, it is now agreed that path_MMR carriers have mul-
tiple MMR deficient/MSI cells in macroscopically normal
looking crypts in the colorectal epithelium, and that CRC
may develop directly from these without a macroscopic-
ally visible adenoma precursor [30, 31]. There is a devel-
oping understanding that MSI cells present neoantigens
on their surfaces that are detectable by the host immune
system, making them targets for destruction by the host
[32]. Whether or not one of the MMR deficient crypts de-
velops into a CRC may be dependent upon the mutator
phenotype rendering a progenitor cell capable of evading
the host immune system [33].
The current paper does not aim to discuss these im-
munological and commonly agreed mechanisms in detail.
They are presented and discussed elsewhere, but the topic
is offered as supporting evidence that MSI cells may be
killed by the host immune system. The probability that a
path_MMR carrier develops CRC may be considered a
balance between the probability of developing precancer-
ous cells and the probability that the immune system will
kill them before they become invasive cancers.
Our offered hypothesis is based on spontaneous regres-
sion of cancers. The case report by Karakuchi et al. of
spontaneous regression of an MSI high cancer in the trans-
verse colon, assumed to be caused by non-germline ac-
quired somatic MMR mutations but not tested to exclude
germline pathogenic variants, is supportive [34]. This does
not exclude other mechanisms, as mentioned above.
Clearly, carcinogenesis is a multifactorial process and
other biological explanations may be offered. If our inter-
pretation of the findings we describe above contains some
truth, it does not imply that other hypotheses – including
the accelerated adenoma-carcinoma sequence, the possibly
important role of missed lesions during suboptimal surveil-
lance colonoscopy, and cancers developing without a de-
tectable and therefore intervention-susceptible precursor
lesion – are not true. We cannot completely exclude an
important influence of variable quality of endoscopy or
some other geographical variable in response to sur-
veillance but the simplest and most persuasive explan-
ation is that having progressed quickly, often from an
unrecognizable precursor, a proportion of these cancers
regress spontaneously and those that survive tend to re-
main as a localized lesion, unlikely to metastasize early.
Conclusions
The PLSD was designed to examine whether or not the
expectations derived from current paradigms alone are
met, with the basic understanding that if current para-
digms may not completely explain what we find, there
may be additional instrumental factors to consider. The
combined epidemiological results from the PLSD now
raise the possibility that some LS-associated CRCs may
spontaneously regress. We can find no published epi-
demiological evidence on the effects of surveillance col-
onoscopy, which are in conflict with our hypothesis. The
concept of over-diagnosis is well established in other
fields of cancer screening. The growing body of knowledge
on how the host immune system fights abnormal cells in
path_MMR carriers may be interpreted as support for our
hypothesis. We suggest that the hypothesis presented here
should be further tested because of its scientific interest
and especially because the consequences would be of
interest to the path_MMR carriers and to the providers of
health care. A controlled study comparing the longest safe
colonoscopy interval to the shortest possible interval
should be able to elucidate the existence of possible
over-diagnosis caused by intense monitoring.
Abbreviations
AJCC: American Joint Committee on Cancer; CRC: Colorectal cancer;
HNPCC: Hereditary nonpolyposis colorectal cancer; LS: Lynch Syndrome;
MMR: Mismatch repair; path_MLH1: Pathogenic (disease-causing) variant of
the MLH1 gene; path_MSH2: Pathogenic (disease-causing) variant of the
MSH2 gene; path_MSH6: Pathogenic (disease-causing) variant of the MSH6
gene; path_PMS2: Pathogenic (disease-causing) variant of the PMS2 gene
Acknowledgements
We would like to express our gratitude to Heikki Järvinen, Beatrix Alcala-Repo
and Marianne Haeusler for their efforts during the years.
Funding
TTS is supported by the Emil Aaltonen Foundation, the Finnish Medical
Foundation, the Instrumentarium Science Foundation and Sigrid Juselius
Foundation.
DGE and EJC are both supported through the National Institute for Health
Research Manchester Biomedical Research Centre (IS-BRC-1215-20007).
The Finnish contribution: The Finnish Cancer Foundation, Jane and Aatos
Erkko foundation and State Research Funding.
The Spanish contribution: Spanish Ministry of Economy and Competitiveness,
the Carlos III Health Institute, the Scientific Foundation Asociación Española
Contra el Cáncer and the Government of Catalonia.
The Welsh Contribution: Wales Gene Park.
The Norwegian contribution: Norwegian Cancer Society, contract
194751–2017 for funding.
The study sponsors did not have a role in planning the study design; in the
collection, analysis, or interpretation of data; in the writing of the report; or
in the decision to submit the paper for publication.
Seppälä et al. Hereditary Cancer in Clinical Practice            (2019) 17:8 Page 6 of 8
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request. We have published a
website www.lscarisk.org on which cancer risks for all published data can be
reviewed and calculated in graphic form.
Authors’ contributions
TTS and PM designed the study, drafted the manuscript, collected the
feedback and revised the manuscript accordingly. TTS conducted the
statistical analysis. PM and MD-V managed the PLSD data. All authors
participated in PLSD data collection. All authors read, critically commented,
and approved the final manuscript.
Ethics approval and consent to participate
All reporting centers obtained informed consent for genetic testing and
surveillance procedures. De-identified data was exported for the current study.
No named registry needing approval was established for the current study.
Consent for publication
Not applicable.
Competing interests
Toni Seppälä: a co-owner (20%) of Healthfund Finland Oy (educational and
health care services in Finland, not related to patients or scope of this manu-
script). Travel costs to a scientific meeting by Medtronic Finland.
John Burn: a patent for high speed low cost tumor profiling pending to
John Burn and QuantuMDx.
All others: None declared.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Surgery, Helsinki University Central Hospital, P.O. Box 340,
00029 HUS Helsinki, Finland. 2University of Helsinki, Helsinki, Finland.
3Heidelberg University Hospital and DKFZ, Heidelberg, Germany.
4Department of Tumor Biology, Institute of Cancer Research, The Norwegian
Radium Hospital, part of Oslo University Hospital, Olso, Norway. 5Department
of Medical Genetics, The Norwegian Radium Hospital, Oslo University
Hospital, Oslo, Norway. 6The Royal Melbourne Hospital, Melbourne, Australia.
7University of Melbourne, Melbourne, Australia. 8University of Manchester &
Manchester University Hospitals Foundation Trust, Manchester, UK. 9The
Danish HNPCC Register, Clinical Research Centre, Copenhagen University
Hospital, Hvidovre, Denmark. 10Medical Genetics, Cardiff University, Cardiff,
UK. 11University of Newcastle and the Hunter Medical Research Institute,
Callaghan, Australia. 12University of Newcastle, Newcastle upon Tyne, UK.
13University Witten-Herdecke, Wuppertal, Germany. 14Dept. of Surgical
Gastroenterology, Aalborg University Hospital, Aalborg, Denmark.
15Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der
Universität München, Munich, Germany. 16MGZ- Medical Genetics Center,
Munich, Germany. 17Central Finland Central Hospital, Education and
Research, Jyväskylä, Finland. 18Department of Clinical Genetics, Aalborg
University Hospital, Aalborg, Denmark. 19Karolinska Institutet, Stockholm,
Sweden. 20Hadassah Medical Center, Jerusalem, and Sheba Medical Center,
Tel-Hashomer, Ramat-Gan, Israel. 21Institute of Human Genetics, University of
Bonn, Bonn, Germany. 22Department of Internal Medicine I, University
Hospital Bonn, Bonn, Germany. 23Center for Hereditary Tumor Syndromes,
University Hospital Bonn, Bonn, Germany. 24Institute for Medical Genetics
and Pathology, University Hospital Basel, Basel, Switzerland. 25Hospital
Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones
Oncológicas Hereditarias (GCU), Montevideo, Uruguay. 26Tel-Aviv Soursky
Medical Center, Tel-Aviv, Israel. 27Department of Gastroenterology and
Hepatology, Isala Clinics, Zwolle, The Netherlands. 28Department of
Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden,
The Netherlands. 29Institute for Medical Informatics, Statistics and
Epidemiology, University of Leipzig, Leipzig, Germany. 30Medical School,
Institute of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany.
31Department of Medicine, Knappschaftskrankenhaus, Ruhr-University
Bochum, Bochum, Germany. 32St Mark’s Hospital, Department of Surgery and
Cancer, Imperial College London, London, UK. 33University of Manchester
and St Mary’s Hospital, Manchester, UK. 34Hereditary Cancer Program, Catalan
Institute of Oncology, Insititut d’Investigació Biomèdica de Bellvitge (IDIBELL),
ONCOBELL Program, L’Hospitalet de Llobregat, Barcelona, Spain. 35Centro de
Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.
36University Medical Center Groningen, Groningen, the Netherlands. 37Leids
Universitair Medisch Centrum, Leiden, Netherlands. 38Department of Surgical
Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. 39Department
of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. 40Center for
Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway.
41Department of Medical Genetics, Aarhus University Hospital, Aarhus,
Denmark. 42Department of Surgery, Central Finland Central Hospital,
Jyväskylä, Finland. 43Faculty of Sport and Health Sciences, University of
Jyväskylä, Jyväskylä, Finland. 44University of Oslo, Oslo, Norway. 45Harvard
School of Public Health, Boston, MA, USA.
Received: 30 January 2019 Accepted: 20 February 2019
References
1. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma--carcinoma sequence
in large bowel. Lancet. 1978;1:245–7.
2. Mecklin JP. Frequency of hereditary colorectal carcinoma. Gastroenterology.
1987;93:1021–5.
3. Jass JR, Stewart SM. Evolution of hereditary non-polyposis colorectal cancer.
Gut. 1992;33:783–6.
4. Järvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate
in families with hereditary nonpolyposis colorectal cancer. Gastroenterology.
1995;108:1405–11.
5. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA,
Peltomäki P, et al. Controlled 15-year trial on screening for colorectal
cancer in families with hereditary nonpolyposis colorectal cancer.
Gastroenterology. 2000;118:829–34.
6. Weigl K, Jansen L, Chang-Claude J, Knebel P, Hoffmeister M, Brenner H.
Family history and the risk of colorectal cancer: the importance of patients'
history of colonoscopy. Int J Cancer. 2016;139:2213–20.
7. Morois S, Cottet V, Racine A, Clavel-Chapelon F, Carbonnel F, Bastide N, et
al. Colonoscopy reduced distal colorectal cancer risk and excess cancer risk
associated with family history. Cancer Causes Control. 2014;25:1329–36.
8. Hennink SD, van der Meulen-de Jong AE, Wolterbeek R, ASLP C, MCJM B,
WFSJ C, et al. Randomized comparison of surveillance intervals in familial
colorectal Cancer. J Clin Oncol. 2015;33:4188–93.
9. Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-
polyposis colorectal cancer (lynch syndrome). Lancet. 1995;345:1183–4.
10. Vasen HFA, Abdirahman M, Brohet R, Langers AMJ, Kleibeuker JH, van
Kouwen M, et al. One to 2-year surveillance intervals reduce risk of
colorectal cancer in families with lynch syndrome. Gastroenterology. 2010;
138:2300–6.
11. Vasen HFA, Blanco I, Aktán-Collán K, Gopie JP, Alonso A, Aretz S, et al. Revised
guidelines for the clinical management of lynch syndrome (HNPCC):
recommendations by a group of European experts. Gut. 2013;62:812–23.
12. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et
al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:
812–6.
13. Peltomäki P, Aaltonen LA, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, et
al. Genetic mapping of a locus predisposing to human colorectal cancer.
Science. 1993;260:810–2.
14. Lindblom A, Tannergård P, Werelius B, Nordenskjöld M. Genetic mapping of
a second locus predisposing to hereditary non-polyposis colon cancer. Nat
Genet. 1993;5:279–82.
15. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The
human mutator gene homolog MSH2 and its association with hereditary
nonpolyposis colon cancer. Cell. 1993;75:1027–38.
16. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al.
Mutations of two PMS homologues in hereditary nonpolyposis colon
cancer. Nature. 1994;371:75–80.
17. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M,
et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis
colorectal cancer. Nat Genet. 1997;17:271–2.
18. Boland CR, Troncale FJ. Familial colonic cancer without antecedent
polyposis. Ann Intern Med. 1984;100:700–1.
Seppälä et al. Hereditary Cancer in Clinical Practice            (2019) 17:8 Page 7 of 8
19. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al.
Cancer incidence and survival in lynch syndrome patients receiving
colonoscopic and gynaecological surveillance: first report from the
prospective lynch syndrome database. Gut. 2017;66:464–72.
20. Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al.
Incidence of and survival after subsequent cancers in carriers of pathogenic
MMR variants with previous cancer: a report from the prospective lynch
syndrome database. Gut. 2017;66:1657–64.
21. Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et
al. Cancer risk and survival in path_MMR carriers by gene and gender up to
75 years of age: a report from the prospective lynch syndrome database.
Gut. 2018;67:1306–16.
22. Seppälä T, Pylvanainen K, Evans DG, Järvinen H, Renkonen-Sinisalo L,
Bernstein I, et al. Colorectal cancer incidence in path_MLH1 carriers
subjected to different follow-up protocols: a prospective lynch syndrome
database report. Hered Cancer Clin Pract. 2017;15:18. https://doi.org/10.
1186/s13053-017-0078-5.
23. Engel C, Vasen HF, Seppälä T, Aretz S, Bigirwamungu-Bargeman M, de Boer
SY, et al. No difference in colorectal Cancer incidence or stage at detection
by colonoscopy among 3 countries with different lynch syndrome
surveillance policies. Gastroenterology. 2018;155:1400–2.
24. Rees CJ, Thomas Gibson S, Rutter MD, Baragwanath P, Pullan R, Feeney M,
et al. UK key performance indicators and quality assurance standards for
colonoscopy. Gut. 2016;65:1923–9.
25. Haanstra JF, Vasen HFA, Sanduleanu S, van der Wouden EJ, Koornstra JJ,
Kleibeuker JH, et al. Quality colonoscopy and risk of interval cancer in lynch
syndrome. Int J Color Dis. 2013;28:1643–9.
26. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with
mammography. Cochrane Breast Cancer Group, editor. Cochrane Database
Syst Rev. 2013;156:CD001877.
27. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-
up for breast cancer incidence and mortality of the Canadian National
Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366.
28. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl P-H. Breast Cancer screening in
Denmark: a cohort study of tumor size and Overdiagnosis. Ann Intern Med
Am Coll Physicians. 2017;166:313–23.
29. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate
cancer. Cochrane Urology Group, editor. Cochrane Database Syst Rev. 2013;
(107):CD004720.
30. Kloor M, Huth C, Voigt AY, Benner A, Schirmacher P, Knebel-Doeberitz von
M, et al. Prevalence of mismatch repair-deficient crypt foci in lynch
syndrome: a pathological study. Lancet Oncol. 2012;13:598–606.
31. Ahadova A, Gallon R, Gebert J, Ballhausen A, Endris V, Kirchner M, et al.
Three molecular pathways model colorectal carcinogenesis in lynch
syndrome. Int J Cancer. 2018;143:139–50.
32. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP,
et al. Immune response against frameshift-induced Neopeptides in
HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology.
2008;134:988–97.
33. Kloor M, Knebel-Doeberitz von M. The immune biology of microsatellite-
unstable Cancer. Trends Cancer. 2016;2:121–33.
34. Karakuchi N, Shimomura M, Toyota K, Hinoi T, Yamamoto H, Sadamoto S, et
al. Spontaneous regression of transverse colon cancer with high-frequency
microsatellite instability: a case report and literature review. World J Surg
Oncol. 2019;17:19.
35. Stormorken AT, Clark N, Grindedal E, Mæhle L, Møller P. Prevention of
colorectal cancer by colonoscopic surveillance in families with hereditary
colorectal cancer. Scand J Gastroenterol. 2007;42:611–7.
36. Mecklin J-P, Aarnio M, Läärä E, Kairaluoma MV, Pylvänäinen K, Peltomäki P,
et al. Development of colorectal tumors in colonoscopic surveillance in
lynch syndrome. Gastroenterology. 2007;133:1093–8.
37. Pylvänäinen K, Kairaluoma M, Mecklin J-P. Compliance and satisfaction
with long-term surveillance in Finnish HNPCC families. Familial Cancer.
2006;5:175–8.
38. Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A. Adenoma
prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut.
2002;50:228–34.
39. Forsberg A, Kjellström L, Andreasson A, Jaramillo E, Rubio CA, Björck E, et al.
Colonoscopy findings in high-risk individuals compared to an average-risk
control population. Scand J Gastroenterol. 2015;50:866–74.
40. Olsen KR, Bojesen SE, Gerdes A-MM, Lindorff-Larsen K, Bernstein IT. Cost-
effectiveness of surveillance programs for families at high and moderate risk
of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health
Care. 2007;23:89–95.
41. Newton K, Green K, Lalloo F, Evans DG, Hill J. Colonoscopy screening
compliance and outcomes in patients with lynch syndrome. Color Dis.
2015;17:38–46.
Seppälä et al. Hereditary Cancer in Clinical Practice            (2019) 17:8 Page 8 of 8
